Editorial: MSC-Derived Extracellular Vesicles and Secreted Factors as “Cell-Free” Therapeutic Alternatives in Regenerative Medicine
Enrico Ragni
Ornella Parolini
Antonietta Rosa Silini- 1IRCCS Istituto Ortopedico Galeazzi, Laboratorio di Biotecnologie Applicate All’Ortopedia, Milano, Italy
- 2Department of Life Science and Public Health, Università Cattolica Del Sacro Cuore, Rome, Italy
- 3Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS, Rome, Italy
- 4Centro di Ricerca E. Menni, Fondazione Poliambulanza- Istituto Ospedaliero, Brescia, Italy
Editorial on the Research Topic
MSC-Derived Extracellular Vesicles and Secreted Factors as “Cell-Free” Therapeutic Alternatives in Regenerative Medicine
In recent years, the concept of “regenerative medicine” has gained interest in the clinical scenario. Within this broad field, mesenchymal stromal cells (MSCs) have paved the way for their potential to stimulate reparative and anti-inflammatory mechanisms to restore healthy functions in damaged organs and tissues (Gomez-Salazar et al., 2020). All these features are ascribed to MSCs capacity to interact with the diseased environment and release soluble mediators, both free and conveyed within extracellular vesicles (EVs) (Phinney and Pittenger, 2017), collectively termed the “secretome”. For these reasons, one of MSCs “fathers”, Prof. Arnold Caplan, in 2011 defined MSCs as an “injury drugstore” (Caplan and Correa, 2011) and recently proposed a nomenclature change in “medicinal signaling cells” (Caplan, 2017). Accordingly, MSC secretomes have repeatedly shown both in vitro and in vivo to maintain several features of the cells from which they derive, and are increasingly been used for both regenerative and immune modulatory applications (Harman et al., 2021).
Due to these reasons, the secretome itself or its constituents (cytokines/chemokines, EVs and embedded molecules) were assumed to serve as a cell-free option in the field of regenerative medicine (Pokrovskaya et al., 2020), avoiding controversial issues related to conventional cell-based therapies (Lukomska et al., 2019). In this frame, several protocols have been developed for MSC-EVs production under good manufacturing practice (Wei et al., 2021), and many clinical trials are currently completed or recruiting (Maumus et al., 2020). Nevertheless, several critical issues have been put aside in the excitement to pursue clinical trials. In particular, a thorough dissection of EVs potential, starting from their rigorous characterization to in vitro/in vivo evidence, is sometimes missing or underestimated. These deficiencies and pitfalls greatly limit MSC-EVs translation into clinical practice, ultimately dampening their therapeutic potential and opening the door to unsatisfactory effects.
This Research Topic presents cutting edge and innovative data on MSC secretome-based research, encompassing both innovative and, when possible, clinical production scalable characterization methods and new results in different disease settings, to select the most characterized and data-driven MSC-based cell free product.
The first step to frame the MSC secretome, and in particular EVs, is a thorough and reliable definition of techniques and parameters with the choice of the most appropriate isolation procedure being a crucial issue. To this end, Phan et al. proposed several methods to effectively and uniformly isolate MSC-EVs from complex biological milieu. By using multiple techniques including optical, non-optical and high-resolution single vesicle characterization methods, the authors clearly showed that isolation techniques greatly influence EVs composition and biological properties. In particular, not a single but multiple and complimentary techniques are crucial to reliably evaluate EVs potential on a more complex level. In this frame, the need of reliable albeit easy to manage protocols is mandatory. Ragni et al. showed how the molecular characterization of EVs, especially for miRNAs, is largely dependent on the selection of the most appropriate reference genes (RGs) since, to date, a universal RG miRNA for MSC-EVs is missing. The authors presented several RG miRNAs for adipose (adipose derived-MSC, ASC)- and bone marrow (bone marrow derived-MSC, BMSC)-derived EVs and, most importantly, showed how an integrated analysis encompassing different EV types is a mandatory step. Finally, Carlomagno et al. exhibited an innovative approach to characterize both EVs and whole secretome based on Raman spectroscopy, which is a non-destructive vibrational investigation method. Their results clearly emphasize how this technique can confirm EVs and secretome isolation reproducibility, a major issue for clinical translation when batch to batch differences depend not only on the source but also on the technical pipeline. These new methodologies will help in accelerating translation to the clinic and regulatory approval reducing concerns related to technical workflow.
The second step for the dissection of the biological role of secretome and EVs requires data on in vitro and preclinical efficacy, allowing in vitro–in vivo correlation of therapeutic potency. When data are largely missing, in vitro analyses are crucial. Ghebes et al. showed how BMSCs ability to support hematopoietic stem cells (HSPCs) expansion relies on EV-shuttled molecules, both proteins and miRNAs, and how the divergent molecular fingerprints in EVs from foetal or adult BMSCs may differentially support ex vivo HSPCs expansion. The issue of molecular signature and composition was also addressed by Zhong et al. in the frame of cardiovascular diseases and heart failure. In an in vitro model of doxorubicin-induced heart failure, miR-100-5p embedded in umbilical cord MSC-EVs inhibited oxidative stress, ROS and apoptosis increase through the direct downregulation of NOX4 expression. A similar role for embedded molecules was shown by Pan et al., who demonstrated the role of lncRNA malat-1 in MSCs-EVs to promote chondrocyte proliferation and repair as well as alleviate cartilage inflammation and degeneration in vitro and in vivo in osteoarthritis models. Consistently, in Qi et al., the use of an animal model allowed to sharply define the modulation of secretome given by the pre-activation of MSCs with serum from colitis rats, which promoted the production of paracrine factors improving the therapeutic effects on the disease. Of note, when data cover a number of different pathologies and indications, a more defined picture may be framed as reported from Cargnoni et al. and Sandonà et al., In the first manuscript related to inflammatory pathologies, perinatal derived EVs were described to directly modulate the immune response by targeting the inflammatory microenvironment. In the second work related to musculoskeletal diseases, MSCs and their secretome were reported to enhance both myofiber regeneration and myogenesis, with EVs postulated as candidates for cell free-based muscle regeneration. In this frame, EVs targeted delivery to the injured site or diseased tissue is another crucial need. To improve the process, Driscoll et al. fabricated an engineered biomaterial composed of EVs cross-linked with graphene oxide and exhibiting cell-type dependent cytotoxicity on liver cancer cells with minimal impact on healthy hepatocytes. Thus, next step in EVs production will be their manipulation under tissue engineering approaches for regenerative medicine.
Altogether, this Research Topic highlights the need for proper EVs characterization and functional studies, both mandatory prerequisites for a faster and bioengineering-driven EVs translation from bench to bedside.
Author Contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Funding
This work was supported by Ministero della Salute Italiano, “Ricerca Corrente”, by the Italian Ministry of Research and University (MIUR, 5 × 1,000 years 2020), and PRIN 2017 program of Italian Ministry of Research and University (MIUR, Grant No. 2017RSAFK7).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Caplan, A. I., and Correa, D. (2011). The MSC: An Injury Drugstore. Cell Stem Cell 9 (1), 11–15. doi:10.1016/j.stem.2011.06.008
Caplan, A. I. (2017). Mesenchymal Stem Cells: Time to Change the Name!. Stem Cell Transl Med 6 (6), 1445–1451. doi:10.1002/sctm.17-0051
Gomez-Salazar, M., Gonzalez-Galofre, Z. N., Casamitjana, J., Crisan, M., James, A. W., and Péault, B. (2020). Five Decades Later, Are Mesenchymal Stem Cells Still Relevant? Front. Bioeng. Biotechnol. 8, 148. doi:10.3389/fbioe.2020.00148
Harman, R. M., Marx, C., and Van de Walle, G. R. (2021). Translational Animal Models Provide Insight into Mesenchymal Stromal Cell (MSC) Secretome Therapy. Front. Cel Dev. Biol. 9, 654885. doi:10.3389/fcell.2021.654885
Lukomska, B., Stanaszek, L., Zuba-Surma, E., Legosz, P., Sarzynska, S., and Drela, K. (2019). Challenges and Controversies in Human Mesenchymal Stem Cell Therapy. Stem Cell Int. 2019, 9628536. doi:10.1155/2019/9628536
Maumus, M., Rozier, P., Boulestreau, J., Jorgensen, C., and Noël, D. (2020). Mesenchymal Stem Cell-Derived Extracellular Vesicles: Opportunities and Challenges for Clinical Translation. Front. Bioeng. Biotechnol. 8, 997. doi:10.3389/fbioe.2020.00997
Phinney, D. G., and Pittenger, M. F. (2017). Concise Review: MSC-Derived Exosomes for Cell-Free Therapy. Stem Cells 35 (4), 851–858. doi:10.1002/stem.2575
Pokrovskaya, L. A., Zubareva, E. V., Nadezhdin, S. V., Lysenko, A. S., and Litovkina, T. L. (2020). Biological Activity of Mesenchymal Stem Cells Secretome as a Basis for Cell-free Therapeutic Approach. Res. Results Pharmacol. 6 (1), 57–68. doi:10.3897/rrpharmacology.6.49413
Keywords: mesenchymal stromal (or stem) cells, extracellular vesicle (EV), secretome, biomaterials, therapeutics
Citation: Ragni E, Parolini O and Silini AR (2022) Editorial: MSC-Derived Extracellular Vesicles and Secreted Factors as “Cell-Free” Therapeutic Alternatives in Regenerative Medicine. Front. Bioeng. Biotechnol. 10:842128. doi: 10.3389/fbioe.2022.842128
Received: 23 December 2021; Accepted: 11 January 2022;
Published: 26 January 2022.
Edited and reviewed by:
Andrea Banfi, University of Basel, SwitzerlandCopyright © 2022 Ragni, Parolini and Silini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ornella Parolini, ornella.parolini@unicatt.it